

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) An antineoplastic dendritic polymer conjugate, comprising:
 - a dendritic polymer conjugated to an antineoplastic agent
 - wherein the dendritic polymer is a poly(amidoamine)dendrimer having carboxylate functional groups,
 - wherein the antineoplastic agent is cisplatin or carboplatin and is encapsulated within the dendritic polymer,
 - wherein the percent by weight of platinum in the conjugate is from 15% to 25%, and
 - wherein the antineoplastic dendritic polymer conjugate has a therapeutic effect on malignant tumors.
2. (cancelled)
3. (cancelled)
4. (cancelled)
5. (cancelled)
6. (cancelled)
7. (cancelled)
8. (cancelled)
9. (cancelled)
10. (cancelled)
11. (cancelled)
12. (currently amended) The antineoplastic dendritic polymer conjugate of claim [10] 1, wherein the dendritic polymer is acrylate derived.

13. (currently amended) The antineoplastic dendritic polymer conjugate of claim [11] 12, where the conjugate is an aggregate[s] of poly(amidoamine) dendrimers of generation 3.5, ethylenediamine core, [as aggrates] with cisplatin [or carboplatin].
14. (currently amended) The antineoplastic dendritic polymer conjugate of claim [4] 1, wherein the molar ratio of the cisplatin [as the antineoplastic agent] to dendritic polymer in the conjugate is from about 100:1 to about 1:1.
15. (currently amended) The antineoplastic dendritic polymer conjugate of claim 13 or 14, wherein the molar ratio of cisplatin to dendritic polymer in the conjugate is about 35:1.
16. (cancelled)
17. (cancelled)
18. (cancelled)
19. (currently amended) The antineoplastic dendritic polymer conjugate of claim [18] 1, wherein the antineoplastic agent [platin-based analogue] is cisplatin [or carboplatin].
20. (new) The antineoplastic dendritic polymer conjugate of claim 1, wherein the poly(amidoamine)dendrimer is a generation from 3.5 to 7.5.